



ALK
Investor Relations Department
BÃ,ge Alle 6-8
Horsholm DK-2970
Denmark

Visit IR website [↗](#)
Sign-up for Email alerts [↗](#)

OMX: ALKB

| | |
|---------------|----------------------------|
| Last Trade: | 795.00 |
| Trade Time: | 4:59 PM ET Jan 16, 2018 |
| Change: | 0.00 (0.000%) |
| Day Range | N/A - N/A |
| 52-Week Range | 681.00 - 1133.00 |
| Volume | 2,542,900 |

Stock information is provided by eSignal,
stock charts provided by EDGAR Online.
Stock data is delayed approximately 20
minutes.

Company Profile

ALK is the world leader in allergy vaccination (immunotherapy). It is the goal of ALK to increase the awareness of the company and its activities through a structured, ongoing, timely and balanced dialogue with investors, shareholders and other stakeholders. It is also a company goal to secure the liquidity of the company's shares and to generate reasonable, long-term returns to shareholders through share price increases and dividends.... [\(more\)](#)

Company releases [\[View all \]](#)

Dec 20, 2017

[ALK — Financial calendar for the 2018 financial year](#)

Dec 11, 2017

[Reporting of transactions with ALK-Abelló A/S' B-shares and associated securities by person closely associated with person discharging managerial responsibly](#)

Dec 11, 2017

[Indberetning af transaktioner med ALK-Abelló A/S' B-aktier og tilknyttede værdipapirer udført af personer med nær tilknytning til personer med ledelsesansvar](#)

Dec 11, 2017

[REGISTRATION OF CAPITAL INCREASE OF DKK 92,076 AA SHARES AND DKK 920,760 B SHARES BY THE ISSUE OF NEW SHARES COMPLETED](#)

Dec 7, 2017

[Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff](#)

Upcoming Events [\[View all \]](#)

Feb 6, 2018

[Annual report 2017](#)

Mar 12, 2018

[AGM](#)